A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero-Incretin Study 1 (SAIS1)

Nomoto, Hiroshi; Miyoshi, Hideaki; Furumoto, Tomoo et al.

PLoS ONE, 2016, 11(10), e0164255

Permalink : https://hdl.handle.net/2115/63828

このアイテムのアクセス数:1,433件（2026-10-06 01:07 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
journal.pone.0164255 pdf 862 KB 665
journal.pone.0164255.s001 DOCX 50.1 KB 296 S1 Consort Checklist
journal.pone.0164255.s002 DOCX 58.3 KB 287 S1 Protocol
journal.pone.0164255.s003 DOC 134 KB 439 S2 Protocol
journal.pone.0164255.s004 XLSX 40.1 KB 238 S1 Table
journal.pone.0164255.s005 XLSX 35.3 KB 188 S2 Table
journal.pone.0164255.s006 TIF 121 KB 386 S3 Table

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/63828
タイトル
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero-Incretin Study 1 (SAIS1)
著者
Nomoto, Hiroshi ; Miyoshi, Hideaki ; Furumoto, Tomoo ; Oba, Koji ; Tsutsui, Hiroyuki ; Inoue, Atsushi ; Atsumi, Tatsuya ; Manda, Naoki ; Kurihara, Yoshio ; Aoki, Shin
著者名
Nomoto, Hiroshi
e-Rad_Researcher
30360902
著者名
Miyoshi, Hideaki
e-Rad_Researcher
10399925
著者名
Furumoto, Tomoo
e-Rad_Researcher
30422926
著者名
Oba, Koji
e-Rad_Researcher
70264017
著者名
Tsutsui, Hiroyuki
著者名
Inoue, Atsushi
e-Rad_Researcher
20301905
著者名
Atsumi, Tatsuya
著者名
Manda, Naoki
著者名
Kurihara, Yoshio
著者名
Aoki, Shin
言語
英語
発行日
2016-10-06
出版者
The Public Library of Science
収録物名
PLoS ONE
巻(号)
11(10)
ページ
e0164255
抄録
Objectives; The DPP-4 inhibitors are incretin-related drugs that improve hyperglycemia in a glucose-dependent manner and have been reported to exert favorable effects on atherosclerosis. However, it has not been fully elucidated whether DPP-4 inhibitors are able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of sitagliptin, a DPP-4 inhibitor, on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride. Materials and Methods: In this multicenter, prospective, randomized parallel-group comparison study, 103 outpatients with type 2 diabetes (aged 59.9 +/- 9.9 years with HbA1c levels of 7.5 +/- 0.4%) with dietary cure only and/or current metformin treatment were enrolled and randomly assigned to receive sitagliptin or glimepiride therapy once daily for 26 weeks. Flow-mediated dilation (FMD), a comprehensive panel of hemodynamic parameters (Task Force(R) Monitor), and serum metabolic markers were assessed before and after the treatment. Results: During the study period, no statistically significant change in %FMD was seen in both groups (sitagliptin, 5.6 to 5.6%; glimepiride, 5.6 to 6.0%). Secretory units of islets in transplantation, TNF-α, adiponectin and biological antioxidant potential significantly improved in the sitagliptin group, and superoxide dismutase also tended to improve in the sitagliptin group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different. Conclusions: Regardless of glycemic improvement, early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta-cell function and on inflammatory and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
権利情報
Creative Commons Attribution 4.0 International
PISSN
1932-6203
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1371/journal.pone.0164255